Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS-associated malignancies

S E Krown1

  • 1Clinical Immunology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Kaposi sarcoma: the role of interferon and thalidomide.

Current opinion in oncology·2001
Same author

Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1999
Same author

Clinical overview: issues in Kaposi's sarcoma therapeutics.

Journal of the National Cancer Institute. Monographs·1998
Same author

Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research·1998
Same author

Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research·1998
Same author

Management of AIDS-associated Kaposi's sarcoma: a multidisciplinary perspective.

Oncology (Williston Park, N.Y.)·1998
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

AIDS-associated malignancies affect 40% of individuals with HIV. Increased survival and more HIV infections in women may lead to a rise in these cancers, with optimal therapies still undefined.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Epidemiology

Background:

  • AIDS-associated malignancies are diagnosed in 40% of HIV-infected individuals.
  • Cancer rates may increase due to prolonged survival and rising HIV rates in women.
  • Children with HIV may also experience increased cancer rates with longer survival.

Purpose of the Study:

  • To review AIDS-defining cancers.
  • To discuss the increasing incidence of common cancers in HIV-infected individuals.
  • To highlight the need for defined optimal therapies for AIDS-associated neoplasms.

Main Methods:

  • Review of epidemiological studies on cancer incidence in HIV-infected populations.
  • Analysis of factors contributing to increased malignancy risk.

Related Experiment Videos

  • Synthesis of current understanding of AIDS-associated malignancy pathogenesis.

    • Main Results:

    • AIDS-defining cancers are prevalent in HIV-infected individuals.
    • Evidence suggests increased rates of common cancers in the HIV-infected population.
    • Pathogenesis of AIDS-associated malignancies is better understood, but optimal treatments are lacking.

    Conclusions:

    • AIDS-associated malignancies pose a significant clinical challenge.
    • The incidence of both AIDS-defining and common cancers is likely to rise in the HIV-infected population.
    • Further research is crucial to define optimal therapeutic strategies for these cancers.